Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-06-24
1999-12-21
McKane, Joseph K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514419, 548469, 548492, 548493, 548504, A61K 31405, C07D20904
Patent
active
060049901
ABSTRACT:
Novel meta substituted arylakylamine compounds are disclosed. These compounds can be administered as small molecule drugs to treat diseases or conditions associated with insufficient serotonin mediated nerve transmission, such as depression and obesity.
REFERENCES:
patent: 3663595 (1972-05-01), Beregi et al.
patent: 3733339 (1973-05-01), Horrom
patent: 3769319 (1973-10-01), Boitze et al.
patent: 3843647 (1974-10-01), Buzas et al.
patent: 3856857 (1974-12-01), Beregi et al.
patent: 3886195 (1975-05-01), Beregi et al.
patent: 3956501 (1976-05-01), Beregi et al.
patent: 4025624 (1977-05-01), Alphin et al.
patent: 4115587 (1978-09-01), Lunsford et al.
patent: 4237165 (1980-12-01), Duhault
patent: 4857553 (1989-08-01), Ward et al.
patent: 4999382 (1991-03-01), Wurtman et al.
Elmaleh, D.R. et al, [.sup.11 C]-N-Methyl and Ethyl Nor-Fenfluramine as Serotonin Ligands for Pet, IXth International Symposium on Radiopharmaceutical Chemistry, Paris, Apr. 6-10 1992.
Appel, N.M. et al., "Effects of High-Dose Fenfluramine Treatment on Monoamine Uptake Sites in Rat Brain: Assessment Using Quantitative Autoradiography" Synapse, vol. 6, pp. 33-44, 1990.
Beckett, A.H. and G.R. Jones, "Metabolic oxidation of aralkyl osimes to nitro compounds by fortified 9000g liver supernatants from various species" J.Pharm. Pharmac., vol. 29, pp. 416-421, 1977.
Coquerel, G., "Interactions During Crystallization Between Enantiomers of Norfenfluramine Dichloracetamide (DICAMIDNF)" Journal of Crystal Growth, vol. 98, pp. 853-854, 1989.
Coquerel, G. et al., "Optical Resolution of (.sup.+ I-)-N-Acylnorfenfluramine Derivatives by Preferential Crystallizaton" Tetrahedron Letters, vol. 31, No. 15, pp. 2143-2144, 1990.
Coquerel, G. et al., "Structure of (R)-Nonfenfluramine Dichloroacetate" Acta Cyrst., vol. C44, Part 6, pp. 1017-1020, Jun. 15, 1988.
Dunn, R.I. et al., "A Novel Activity Cate for Rats: Characterization of Some Phenylethylamine Derivatives . . . " Clinical and Experimental Pharmacology Physiology, vol. 5, pp. 627-633, 1978.
Elmaleh, D.R. et al, "The In-Vivo Behavior of D- and L-[C-11]-N-Methylnorfenfluramine . . . " Abstract No. 03124, The Society of Nuclear Medicine 40th Annual Meeting, Toronto, Canada: Jun. 8-11 1993.
Fuller, R.W., "Effect of nonfenfluramine and two structural analogues on brain 5-hydroxyindoles and serum prolactin in rats" J. Pharm. Pharmacol., vol. 34, pp. 449-450, 1982.
Garattini, S. et al., "Progress report on the anorexia induced by drugs believed to mimic some of the effects of serotonin on the central nervous system" Am J Clin Nutr, vol. 55, pp. 160S-166S, 1992.
Gardier, A.M. et al., "Autoreceptor Control of Changes in Brain Serotonin Release and Metabolism Induced by Repeated Administratioin of High Doses of Anorectic Serotoninergic Drugs" Brain Research (In Press).
Gobbi, M. et al., "In-vivo (+)-[.sup.3 H]Fenfluramine Binding to Rat Brain: Biochemical and Autoradiographic Studies" J. Pharm. Pharmacol., vol. 41, pp. 253-256, 1989.
Gray, N.M. et al., "The Effects of Stereoisomers of 2-Amino-6(7)- and 9-Amino-6-Trifluoromethylbenzonorbornenes on Food Intake, . . . " Pharmacological Research Communications, vol. 16, No. 3, pp. 281-294.
Grunewald, G.L. et al., "Binding Orientation of Amphetamine and Norfenfluramine Analogues in the Benzonorbornene and Benzobicyclo[3.2.1]octane Ring Systems . . . " J. Med. Chem., vol. 30, pp. 2191-2208, 1987.
Grunewald, G.L. et al., "Synthesis of Conformationally Defined Analogues of Norfenfluramine. A Highly Stereospecific Synthesis of Amines from Alcohols in the Benzobicyclo[2.2.1]heptene System" J. Org. Chem., vol. 48, pp. 2321-2327, 1983.
Lafferrere, B. and R.J. Wurtman, "Effect of D-fenfluramine on serotonin release in brains of anaesthetized rats" Brain Research, vol. 504, pp. 258-263, 1989.
Meng, X. et al., "[C-11]-N-Methyl and Ethyl Nor-Fenfluramine as a Serotonin Ligands for Pet" Abstract No. 03085, The Society of Nuclear Medicine 39th Annual Meeting, Los Angeles, CA: Jun. 9-12 1992.
Meng, X.-J. et al., "[I-125]-N-(E)-3-Iodo-Allyl-D(L) Norfenfluramine" Abstract No. 03134, The Society of Nuclear Medicine 40th Annual Meeting, Toronto, Canada: Jun. 8-11 1993.
Mennini, T. et al., "Characterization of High Affinity and Stereospecific [.sup.3 H]d-Fenfluramine Binding to Rat Brain" Neurochem. Int., vol. 13, No. 3, pp. 345-351, 1988.
Offermeir, J. and B. Potgieter, "Some effects of fenfluramine and its derivatives on the central catecholaminergic systems of mice" Postgraduate Medical Journal, vol. 51 (Suppl. 1), pp. 65-71, 1975.
Pritchard P.H. and D.N. Brindley, "Studies on the ethanol-induced changes in glycerolipid systhesis in rats and their partial reversal by N-(2-benzoyloxyethyl) norfenfluramine (benfluorex)" J. Pharm. Pharmac., vol. 29, pp. 343-349, 1977.
Ricaurte, G.A. et al., "Dexfenfluramine neurotoxicity in brains of non-human primates" the Lancet, vol. 338, pp. 1487-1488, Dec. 14, 1991.
Sarkissian, C.F. et al., "Effects of fluoxetine or D-fenfluramine on serotonin release from, and levels in, rat frontal cortex" Brain Research, Vo. 529, pp. 294-301, 1990.
Scheffel, U. and G.A. Ricaurte, "Paroxetine as an in vivo indicator of methylenedioxymethamphetamine" vol. 527, pp. 89-95, 1990.
Zwarenstein, H. and N. Sapeika, "Effect of a Norfenfluramine Derivative (S780) on NADH Dehydrogenase . . . " Research Communications in Chemical Pathology and Pharmacology, vol. 5, No. 1, pp. 233-236, Jan. 1973.
Elmaleh David R.
Fischman Alan J.
McKane Joseph K.
Zebra Pharmaceuticals
LandOfFree
Meta substituted arylalkylamines and therapeutic and diagnostic does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Meta substituted arylalkylamines and therapeutic and diagnostic , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Meta substituted arylalkylamines and therapeutic and diagnostic will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-505621